Document Detail

Review of biomarkers in colorectal cancer.
MedLine Citation:
PMID:  21040359     Owner:  NLM     Status:  MEDLINE    
AIM: Advances in molecular technology have resulted in the discovery of many putative biomarkers relevant to colorectal cancer (CRC).
METHOD: Literature searches were performed on PubMed and EMBASE using the words 'colorectal cancer', AND 'biomarkers OR markers'. Biomarkers that are either currently in clinical use or have potential clinical use were identified.
RESULTS: Most potential markers are in the discovery phase waiting to undergo clinical validation. Hypermethylation of the plasma septin-9 gene shows promise as a nonstool-based screening tool. Hypermethylation of the DYPD gene (encodes the enzyme dihydropyrimidine dehydrogenase) and variation of the uridine diphosphate-glucuronosyltransferase 1A (UGT1A1) gene have predictive value for side effects and the efficacy of 5-fluoruracil and irinotecan, respectively. Mismatch repair protein immunohistochemistry is able to predict response to 5-fluorouracil, and the KRAS (Kirsten rat sarcoma viral oncogene) and B-RAF (v-RAF murine sarcoma viral oncogene homolog B1) somatic gene mutation status can predict the response to anti-epidermal growth factor receptor therapy.
CONCLUSION: Recent advances indicate that the widespread use of biomarkers may herald the next major advance in the diagnosis and management of CRC.
K F Newton; W Newman; J Hill
Related Documents :
16053659 - Tailored therapy of colorectal cancer: results, challenges and future directions.
11984099 - Applications of advances in molecular biology and genomics to clinical cancer care.
19089739 - Triple-negative/basal-like breast cancer: review.
24996829 - The importance of good death components among cancer patients, the general population, ...
21136759 - Quantitative proteomics for identification of cancer biomarkers.
21243449 - Approach to venous thromboembolism in the cancer patient.
19335749 - Endothelin receptor antagonism and cancer.
12429069 - The transitive fallacy for randomized trials: if a bests b and b bests c in separate tr...
23506979 - High expression of microrna-625-3p is associated with poor response to first-line oxali...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland     Volume:  14     ISSN:  1463-1318     ISO Abbreviation:  Colorectal Dis     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-07     Completed Date:  2012-04-04     Revised Date:  2012-04-10    
Medline Journal Info:
Nlm Unique ID:  100883611     Medline TA:  Colorectal Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  3-17     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.
Department of General Surgery, Manchester Royal Infirmary Department of Genetic Medicine, Manchester Academic Health Science Centre, Central Manchester University Hospitals Trust, Manchester, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / therapeutic use
Colorectal Neoplasms / diagnosis,  drug therapy,  genetics*
Diagnosis, Differential
Genetic Predisposition to Disease
Genome-Wide Association Study
Mass Screening
Predictive Value of Tests
Risk Assessment
Tumor Markers, Biological*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Tumor Markers, Biological
Comment In:
Colorectal Dis. 2012 Apr;14(4):522-3   [PMID:  22251273 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculo...
Next Document:  Endorectal elastography in the evaluation of rectal tumours.